vs

Side-by-side financial comparison of CELESTICA INC (CLS) and Quest Diagnostics (DGX). Click either name above to swap in a different company.

CELESTICA INC is the larger business by last-quarter revenue ($4.0B vs $2.9B, roughly 1.4× Quest Diagnostics). Quest Diagnostics runs the higher net margin — 9.7% vs 5.2%, a 4.5% gap on every dollar of revenue. On growth, CELESTICA INC posted the faster year-over-year revenue change (52.8% vs 9.2%). Over the past eight quarters, CELESTICA INC's revenue compounded faster (35.4% CAGR vs 9.9%).

Celestica Inc. is a Canadian multinational design, manufacturing, hardware platform, and supply chain electronics manufacturing services (EMS) company, which is headquartered in Toronto, Ontario. The company operates in 50 sites across 15 countries.

Quest Diagnostics Incorporated is an American clinical laboratory. A Fortune 500 company, Quest operates in the United States, Puerto Rico, Mexico, and Brazil. Quest also maintains collaborative agreements with various hospitals and clinics across the globe.

CLS vs DGX — Head-to-Head

Bigger by revenue
CLS
CLS
1.4× larger
CLS
$4.0B
$2.9B
DGX
Growing faster (revenue YoY)
CLS
CLS
+43.6% gap
CLS
52.8%
9.2%
DGX
Higher net margin
DGX
DGX
4.5% more per $
DGX
9.7%
5.2%
CLS
Faster 2-yr revenue CAGR
CLS
CLS
Annualised
CLS
35.4%
9.9%
DGX

Income Statement — Q1 FY2026 vs Q1 FY2026

Metric
CLS
CLS
DGX
DGX
Revenue
$4.0B
$2.9B
Net Profit
$212.3M
$281.0M
Gross Margin
10.8%
Operating Margin
6723.5%
15.4%
Net Margin
5.2%
9.7%
Revenue YoY
52.8%
9.2%
Net Profit YoY
146.3%
12.0%
EPS (diluted)
$1.83
$2.24

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CLS
CLS
DGX
DGX
Q1 26
$4.0B
$2.9B
Q4 25
$3.7B
$2.8B
Q3 25
$3.2B
$2.8B
Q2 25
$2.9B
$2.8B
Q1 25
$2.6B
$2.7B
Q4 24
$2.6B
Q3 24
$2.5B
$2.5B
Q2 24
$2.4B
$2.4B
Net Profit
CLS
CLS
DGX
DGX
Q1 26
$212.3M
$281.0M
Q4 25
$267.5M
$245.0M
Q3 25
$267.8M
$245.0M
Q2 25
$211.0M
$282.0M
Q1 25
$86.2M
$220.0M
Q4 24
$222.0M
Q3 24
$89.5M
$226.0M
Q2 24
$95.0M
$229.0M
Gross Margin
CLS
CLS
DGX
DGX
Q1 26
10.8%
Q4 25
11.8%
32.4%
Q3 25
13.0%
33.7%
Q2 25
12.8%
34.2%
Q1 25
10.3%
32.5%
Q4 24
32.7%
Q3 24
10.4%
32.6%
Q2 24
10.6%
33.5%
Operating Margin
CLS
CLS
DGX
DGX
Q1 26
6723.5%
15.4%
Q4 25
8.6%
13.8%
Q3 25
10.2%
13.7%
Q2 25
9.4%
15.9%
Q1 25
4.9%
13.0%
Q4 24
13.8%
Q3 24
5.5%
13.3%
Q2 24
5.6%
14.8%
Net Margin
CLS
CLS
DGX
DGX
Q1 26
5.2%
9.7%
Q4 25
7.3%
8.7%
Q3 25
8.4%
8.7%
Q2 25
7.3%
10.2%
Q1 25
3.3%
8.3%
Q4 24
8.5%
Q3 24
3.6%
9.1%
Q2 24
4.0%
9.6%
EPS (diluted)
CLS
CLS
DGX
DGX
Q1 26
$1.83
$2.24
Q4 25
$2.29
$2.18
Q3 25
$2.31
$2.16
Q2 25
$1.82
$2.47
Q1 25
$0.74
$1.94
Q4 24
$1.95
Q3 24
$0.75
$1.99
Q2 24
$0.80
$2.03

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CLS
CLS
DGX
DGX
Cash + ST InvestmentsLiquidity on hand
$378.0M
$393.0M
Total DebtLower is stronger
$5.7B
Stockholders' EquityBook value
$2.1B
$7.7B
Total Assets
$8260.0B
$16.7B
Debt / EquityLower = less leverage
0.74×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CLS
CLS
DGX
DGX
Q1 26
$378.0M
$393.0M
Q4 25
$595.6M
$420.0M
Q3 25
$305.9M
$432.0M
Q2 25
$313.8M
$319.0M
Q1 25
$303.0M
$188.0M
Q4 24
$549.0M
Q3 24
$764.0M
Q2 24
$271.0M
Total Debt
CLS
CLS
DGX
DGX
Q1 26
$5.7B
Q4 25
$750.5M
$5.2B
Q3 25
$756.7M
$5.2B
Q2 25
$848.6M
$5.2B
Q1 25
$915.0M
$5.9B
Q4 24
$5.6B
Q3 24
$5.6B
Q2 24
$3.8B
Stockholders' Equity
CLS
CLS
DGX
DGX
Q1 26
$2.1B
$7.7B
Q4 25
$2.2B
$7.2B
Q3 25
$2.0B
$7.3B
Q2 25
$1.8B
$7.2B
Q1 25
$1.6B
$6.9B
Q4 24
$6.8B
Q3 24
$1.8B
$6.8B
Q2 24
$1.8B
$6.6B
Total Assets
CLS
CLS
DGX
DGX
Q1 26
$8260.0B
$16.7B
Q4 25
$7.2B
$16.2B
Q3 25
$6.6B
$16.2B
Q2 25
$6.2B
$16.0B
Q1 25
$5.8B
$15.8B
Q4 24
$16.2B
Q3 24
$16.1B
Q2 24
$13.9B
Debt / Equity
CLS
CLS
DGX
DGX
Q1 26
0.74×
Q4 25
0.34×
0.72×
Q3 25
0.37×
0.71×
Q2 25
0.48×
0.72×
Q1 25
0.59×
0.85×
Q4 24
0.83×
Q3 24
0.83×
Q2 24
0.58×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CLS
CLS
DGX
DGX
Operating Cash FlowLast quarter
$356.3M
$278.0M
Free Cash FlowOCF − Capex
$137.9M
FCF MarginFCF / Revenue
3.4%
Capex IntensityCapex / Revenue
3.9%
Cash ConversionOCF / Net Profit
1.68×
0.99×
TTM Free Cash FlowTrailing 4 quarters
$502.6M

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CLS
CLS
DGX
DGX
Q1 26
$356.3M
$278.0M
Q4 25
$250.6M
$465.0M
Q3 25
$126.2M
$563.0M
Q2 25
$152.4M
$544.0M
Q1 25
$130.3M
$314.0M
Q4 24
$464.0M
Q3 24
$122.8M
$356.0M
Q2 24
$99.6M
$360.0M
Free Cash Flow
CLS
CLS
DGX
DGX
Q1 26
$137.9M
Q4 25
$155.9M
$307.0M
Q3 25
$88.9M
$419.0M
Q2 25
$119.9M
$436.0M
Q1 25
$93.6M
$197.0M
Q4 24
$341.0M
Q3 24
$76.8M
$250.0M
Q2 24
$62.7M
$268.0M
FCF Margin
CLS
CLS
DGX
DGX
Q1 26
3.4%
Q4 25
4.3%
10.9%
Q3 25
2.8%
14.9%
Q2 25
4.1%
15.8%
Q1 25
3.5%
7.4%
Q4 24
13.0%
Q3 24
3.1%
10.0%
Q2 24
2.6%
11.2%
Capex Intensity
CLS
CLS
DGX
DGX
Q1 26
3.9%
Q4 25
2.6%
5.6%
Q3 25
1.2%
5.1%
Q2 25
1.1%
3.9%
Q1 25
1.4%
4.4%
Q4 24
4.7%
Q3 24
1.8%
4.3%
Q2 24
1.5%
3.8%
Cash Conversion
CLS
CLS
DGX
DGX
Q1 26
1.68×
0.99×
Q4 25
0.94×
1.90×
Q3 25
0.47×
2.30×
Q2 25
0.72×
1.93×
Q1 25
1.51×
1.43×
Q4 24
2.09×
Q3 24
1.37×
1.58×
Q2 24
1.05×
1.57×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons